Abbott‘s Low-Dose Neuromodulation Implant for Chronic Pain, Proclaim XR, was recently featured at 2020 International CES. Proclaim XR can connect to Apple products via Bluetooth and to enables patients to have more control over their treatment to regulate their pain as needed.
Treatment plans can be updated and modified as new therapies are approved and its internal battery can run for up to ten years without replacement reducing the need for additional surgeries.
Proclaim XR delivers a “low dose” of Abbott’s BurstDR™ stimulation which sends a current that alters pain signals as they travel up the spine instead of overriding them, enabling the device to conserve battery.
Timothy Deer, M.D., DABPM, president and chief executive officer of The Spine and Nerve Center of the Virginias states
“For the 50 million people living with chronic pain in the United States this is a new and exciting treatment… Proclaim XR is a major advancement in spinal cord stimulation, and is an evidence-based therapy that is mobile app-based and features upgradeable software. This means patients won’t need surgery to benefit from future advances in this technology.”
In iData’s most recent report on the U.S. Neurological Devices, the market was estimated to be valued at $4.4 billion in 2019. It is expected to grow at a CAGR of 7.6% to $7.3 billion by 2026.
For Further Information
To get in an in-depth U.S. market analysis which includes interviews and procedural volumes, check out iData Research’s study titled the Neurological Devices Market Analysis, Size, Trends | United States | MedSuite